Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mologen grants lefitolimod rights to iPharma

Executive Summary

Mologen AG and iPharma Ltd. signed a binding term sheet that could culminate with iPharma gaining exclusive rights to develop and sell Mologen’s Phase III oncology project lefitolimod (MGN1703) in China, Hong Kong, Macao, Taiwan, and Singapore.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Preliminary
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register